

Literatura

1. Abdurrahman, G., Schmiedeke, F., Bachert, C. et al. Allergy – A new role for T cell superantigens of *Staphylococcus aureus*? *Toxins (Basel)* 12, 3: 176, 2020.
2. Adatia, A., Wahab, M., Satia, I. Is tezepelumab more than just an anti-eosinophil drug? *Eur Respir J* 59, 1: 2101700, 2021.
3. Agache, I., Akdis, C. A., Akdis, M. et al. EAACI Biologicals Guidelines – Recommendations for severe asthma. *Allergy* 76, 1: 14–44, 2021.
4. Agache, I., Akdis, C., Jutel, M., Virchow, J. C. Untangling asthma phenotypes and endotypes. *Allergy* 67, 7: 835–846, 2012.
5. Agarwal, R. Severe asthma with fungal sensitization. *Curr Allergy Asthma Rep* 11, 5: 403–413, 2011.
6. Akenroye, A., Lassiter, G., Jackson, J. W. et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. *J Allergy Clin Immunol* 150, 5: 1097–1105, 2022.
7. Anderson, G. P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. *Lancet* 372, 9643: 1107–1119, 2008.
8. Anees, W., Huggins, V., Pavord, I. D. et al. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. *Thorax* 57, 3: 231–236, 2002.
9. Antušová, Z., Fila, L., Herout, V. et al. Non-CF bronchiectázie dospělých: stručný přehled pro praxi. *Vnitř Lék* 63, 11: 821–833, 2017.
10. Arber, D. A., Orazi, A., Hasserjian, R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 127, 20: 2391–2405, 2016.
11. Baptist, A. P., Busse, P. J. Asthma over the age of 65: All's well that ends well. *J Allergy Clin Immunol Pract* 6, 3: 764–773, 2018.
12. Barnes, P. J. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? *Clin Exp Allergy* 39, 8: 1145–1151, 2009.
13. Barnes, P. J. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol* 8, 3: 183–192, 2008.
14. Barnes, P. J., Pedersen, S., Busse, W. W. Efficacy and safety of inhaled corticosteroids. New developments. *Am J Respir Crit Care Med* 157, 3 Pt 2: S1–S53, 1998.
15. Bel, E. H., Sousa, A., Fleming, L. et al.; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax* 66, 10: 910–917, 2011.
16. Berry, M., Morgan, A., Shaw, D. E. et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. *Thorax* 62, 12: 1043–1049, 2007.
17. Bhalla, A., Zhao, N., Rivas, D. D. et al. Exacerbations of severe asthma while on Anti-IL-5 biologics. *J Investig Allergol Clin Immunol* 30, 5: 307–316, 2020.
18. Blaiss, M. S., Castro, M., Chipps, B. E. et al. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. *Ann Allergy Asthma Immunol* 119, 6: 533–540, 2017.
19. Bochner, B. S. The eosinophil: For better or worse, in sickness and in health. *Ann Allergy Asthma Immunol* 121, 2: 150–155, 2018.
20. Breiteneder, H., Peng, Y. Q., Agache, I. et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. *Allergy* 75, 12: 3039–3068, 2020.
21. Brusselle, G. G., Koppelman, G. H. Biologic therapies for severe asthma. *N Engl J Med* 386, 2: 157–171, 2022.
22. Brusselle, G., Bracke, K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 11, Supl. 5: S322–S328, 2014.
23. Brusselle, G. G., Vanderstichele, C., Jordens, P. et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. *Thorax* 68, 4: 322–329, 2013.

24. Brusselle, G. G., Maes, T., Bracke, K. R. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. *Nat Med* 19, 8: 977–979, 2013.
25. Brychtová, Y., Doubek, M. Myeloidní a lymfoidní neoplázie s eozinofíi. In: Léčebné postupy v hematologii – aktualizace 2022. Doporučení České hematologické společnosti ČLS JEP, 10.5.2022. (online: www.hematology.cz)
26. Buhl, R., Bel, E., Bourdin, A. et al. Effective management of severe asthma with biologic medications in adult patients: A literature review and international expert opinion. *J Allergy Clin Immunol Pract* 10, 2: 422–432, 2022.
27. Burrows, B., Martinez, F. D., Halonen, M. et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. *N Engl J Med* 320, 5: 271–277, 1989.
28. Busse, W. W., Morgan, W. J., Gergen, P. J. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med* 364, 11: 1005–1015, 2011.
29. Caminati, M., Olivieri, B., Dama, A. et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. *Expert Rev Respir Med* 16, 7: 713–721, 2022.
30. Carr, T. F., Zeki, A. A., Kraft, M. Eosinophilic and noneosinophilic asthma. *Am J Respir Crit Care Med* 197, 1: 22–37, 2018.
31. Castanhinha, S., Sherburn, R., Walker, S. et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. *J Allergy Clin Immunol* 136, 2: 312–322, 2015.
32. Chan, R., Stewart, K., Misirovs, R., Lipworth, B. J. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. *J Allergy Clin Immunol Pract* 10, 6: 1497–1505, 2022.
33. Chang, J. T., Meza, R., Levy, D. T. et al. Prediction of COPD risk accounting for time-varying smoking exposures. *PLoS One* 16, 3: e0248535, 2021.
34. Chen, M. M., Roufousse, F., Wang, S. A. et al. An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes. *J Allergy Clin Immunol Pract* 10, 5: 1217–1228, 2022.
35. Chipps, B. E., Murphy, K. R., Oppenheimer, J. 2020 NAEPP Guidelines update and GINA 2021 – Asthma care differences, overlap, and challenges. *J Allergy Clin Immunol Pract* 10, Supl. 1: S19–S30, 2022.
36. Chung, K. F., Wenzel, S. E., Brozek, J. L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 43, 2: 343–373, 2014.
37. Coverstone, A. M., Seibold, M. A., Peters, M. C. Diagnosis and management of T2-High Asthma. *J Allergy Clin Immunol Pract* 8, 2: 442–450, 2020.
38. Dal Negro, R. W., Tognella, S., Guerriero, M., Micheletto, C. Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity. *Multidiscip Respir Med* 8, 1: 32, 2013.
39. Dávila, I., Quirce, S., Olaguibel, J. M. Selection of biologics in severe asthma: A multifaceted algorithm. *J Investig Allergol Clin Immunol* 29, 4: 325–328, 2019.
40. Diamant, Z., Boot, J. D., Mantzouranis, E. et al. Biomarkers in asthma and allergic rhinitis. *Pulm Pharmacol Ther* 23, 6: 468–481, 2010.
41. Diver, S., Khalfaoui, L., Emson, C. et al. Effect of tezepelumab on airway inflammatory cells, remodeling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med* 9, 11: 1299–1312, 2021.
42. Domingo, C. Overlapping effects of new monoclonal antibodies for severe asthma. *Drugs* 77, 16: 1769–1787, 2017.
43. Doubek, M., Brychtová, Y., Kissová, J. et al. Diferenciální diagnostika eozinofilie. *Vnitř Lék* 60, Supl. 2: 21–27, 2014.
44. Dunican, E. M., Fahy, J. V. Asthma and corticosteroids: time for a more precise approach to treatment. *Eur Respir J* 49, 6: 1701167, 2017.
45. Durrani, S. R., Viswanathan, R. K., Busse, W. W. What effect does asthma treatment have on airway remodeling? Current perspectives. *J Allergy Clin Immunol* 128, 3: 439–448; quiz 449–450, 2011.
46. Eldaibossi, S. A. M., Awad, A., Anshasi, N. Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis – Case series, Almoosa specialist hospital. *Respir Med Case Rep* 34: 101520, 2021.
47. Fauci, A. S., Harley, J. B., Roberts, W. C. et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. *Ann Intern Med* 97, 1: 78–92, 1982.
48. de Jongste, J. C. Impact of treatment on bronchial hyperresponsiveness. *Pediatr Allergy Immunol* 7, Supl. 9: 18–24, 1996.
49. Fitzpatrick, A. M., Chipps, B. E., Holguin, F., Woodruff, P. G. T2-“Low” Asthma: Overview and management strategies. *J Allergy Clin Immunol Pract* 8, 2: 452–463, 2020.
50. Global Initiative for Asthma (GINA). 2025 GINA report, Global strategy for asthma management and prevention. (online: <http://ginasthma.org>)
51. Gibson, P. G., Yang, I. A., Upham, J. W. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet* 390, 10095: 659–668, 2017.
52. Haldar, P., Pavord, I. D., Shaw, D. E. et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med* 178, 3: 218–224, 2008.
53. Hama, N., Abe, R., Gibson, A., Phillips, E. J. Drug-induced hypersensitivity syndrome (DIHS)/Drug reaction with eosinophilia and systemic symptoms (DRESS): Clinical features and pathogenesis. *J Allergy Clin Immunol Pract* 10, 5: 1155–1167, 2022.
54. Hartl, S., Breyer, M. K., Burghuber, O. C. et al. Blood eosinophil count in the general population: typical values and potential confounders. *Eur Respir J* 55, 5: 1901874, 2020.
55. Hatzler, L., Panetta, V., Lau, S. et al. Molecular spreading and predictive value of preclinical IgE response to *Phleum pratense* in children with hay fever. *J Allergy Clin Immunol* 130, 4: 894–901, 2012.
56. Hekking, P. W., Wener, R. R., Amelink, M. et al. The prevalence of severe refractory asthma. *J Allergy Clin Immunol* 135, 4: 896–902, 2015.
57. Heribanová, L. Alergická bronchopulmonální aspergilóza. *Prakt Lék* 94, 2: 59–63, 2014.
58. Holguin, F., Cardet, J. C., Chung, K. F. et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J* 55, 1: 1900588, 2020.
59. Jabbal, S., Lipworth, B. J. Blood eosinophils: The forgotten man of inhaled steroid dose titration. *Clin Exp Allergy* 48, 1: 93–95, 2018.
60. Jack, J., Bajaj, T.. Allergic Bronchopulmonary Aspergillosis. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022.
61. Kai, Y., Yoshikawa, M., Matsuda, M. et al. Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report. *Respir Med Case Rep* 39: 101723, 2022.
62. Katial, R. K., Bensch, G. W., Busse, W. W. et al. Changing paradigms in the treatment of severe asthma: The role of biologic therapies. *J Allergy Clin Immunol Pract* 5, Supl. 2: S1–S14, 2017.
63. Kaur, R., Chupp, G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. *J Allergy Clin Immunol* 144, 1: 1–12, 2019.
64. Kraft, M., Brusselle, G., FitzGerald, J. M. et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. *Eur Respir J* 58, 6: 2100413, 2021.
65. Kurashima, K., Takaku, Y., Ohta, C. et al. Smoking history and emphysema in asthma-COPD overlap. *Int J Chron Obstruct Pulmon Dis* 12: 3523–3532, 2017.
66. Laidlaw, T. M., Boyce, J. A. Aspirin-exacerbated respiratory disease – New prime suspects. *N Engl J Med* 374, 5: 484–488, 2016.
67. Le Floc’h, A., Allinne, J., Nagashima, K. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R α antibody, is required to broadly inhibit type 2 inflammation. *Allergy* 75, 5: 1188–1204, 2020.
68. Lommatzsch, M., Klein, M., Stoll, P., Virchow, J. C. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma. *Thorax* 74, 4: 417–418, 2019.
69. Lommatzsch, M., Brusselle, G. G., Canonica, G. W. et al. Disease-modifying anti-asthmatic drugs. *Lancet* 399, 10335: 1664–1668, 2022.
70. Lommatzsch, M., Suhling, H., Korn, S. et al. Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations. *Allergy* 77, 9: 2839–2843, 2022.
71. Margelidon-Cozzolino, V., Tsicopoulos, A., Chenivresse, C., de Nadai, P. Role of Th17 cytokines in airway remodeling in asthma and therapy perspectives. *Front Allergy* 3: 806391, 2022.

72. Mathur, S. K. Allergy and asthma in the elderly. *Semin Respir Crit Care Med* 31, 5: 587–595, 2010.
73. Matricardi, P. M. Molecular profile clustering of IgE responses and potential implications for specific immunotherapy. *Curr Opin Allergy Clin Immunol* 13, 4: 438–445, 2013.
74. McDowell, P. J., Diver, S., Yang, F. et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. *Lancet Respir Med* 9, 10: 1174–1184, 2021.
75. Menzella, F., Bertolini, F., Biava, M. et al. Severe refractory asthma: current treatment options and ongoing research. *Drugs Context* 7: 212561, 2018.
76. Menzies-Gow, A., Bafadhel, M., Busse, W. W. et al. An expert consensus framework for asthma remission as a treatment goal. *J Allergy Clin Immunol* 145, 3: 757–765, 2020.
77. Menzies-Gow, A., Corren, J., Bourdin, A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med* 384, 19: 1800–1809, 2021.
78. Menzies-Gow, A. N., McBrien, C., Unni, B. et al. Real world biologic use and switch patterns in severe asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. *J Asthma Allergy* 15: 63–78, 2022.
79. Menzies-Gow, A., Wechsler, M. E., Brightling, Ch. E. et al.; DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. *Lancet Respir Med* S2213–2600(22)00492-1, 2023.
80. Milgrom, H., Fick, R. B. Jr., Su, J. Q. et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAB-E25 Study Group. *N Engl J Med* 341, 26: 1966–1973, 1999.
81. Moiseev, S., Bossuyt, X., Arimura, Y. et al.; European EGPA Study Group. International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis. *Am J Respir Crit Care Med*, 2020.
82. Mukherjee, M., Nair, P. Blood or sputum eosinophils to guide asthma therapy? *Lancet Respir Med* 3, 11: 824–825, 2015.
83. Mukherjee, M., Aleman Paramo, F., Kjarsgaard, M. et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. *Am J Respir Crit Care Med* 197, 1: 38–46, 2018.
84. Muraro, A., Lemanske, R. F. Jr., Hellings, P. W. et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol* 137, 5: 1347–1358, 2016.
85. Nagase, H., Suzukawa, M., Oishi, K., Matsunaga, K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. *Allergol Int* 72, 1: 11–23, 2023.
86. Nair, P. Predictors of response to anti-IL-5 biologics. *Respirology* 25, 11: 1123–1125, 2020.
87. Ogbogu, P. U., Bochner, B. S., Butterfield, J. H. et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. *J Allergy Clin Immunol* 124, 6: 1319–1325, 2009.
88. Oishi, K., Matsunaga, K. Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma. *Immun Inflamm Dis* 6, 3: 374–376, 2018.
89. Ortega, H., Chupp, G., Bardin, P. et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. *Eur Respir J* 44, 1: 239–241, 2014.
90. Papaioannou, A. I., Diamant, Z., Bakakos, P., Loukides, S. Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. *Respir Med* 142: 15–22, 2018.
91. Papaioannou, A. I., Fouka, E., Papakosta, D. et al. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. *Clin Exp Allergy* 51, 2: 221–227, 2021.
92. Papadopoulos, N. G., Barnes, P., Canonica, G. W. et al. The evolving algorithm of biological selection in severe asthma. *Allergy* 75, 7: 1555–1563, 2020.
93. Papi, A., Brightling, C., Pedersen, S. E., Reddel, H. K. Asthma. *Lancet* 391, 10122: 783–800, 2018.
94. Pavord, I. D., Hilvering, B., Shrimanker, R. Emerging biologics in severe asthma. *Immunol Allergy Clin North Am* 36, 3: 609–623, 2016.
95. Posa, D., Perna, S., Resch, Y. et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. *J Allergy Clin Immunol* 139, 2: 541–549, 2017.
96. Pavord, I. D., Bel, E. H., Bourdin, A. et al. From DREAM to REALTI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. *Allergy* 77, 3: 778–797, 2022.
97. Pavord, I. D., Barnes, P. J., Lemièrre, C., Gibson, P. G. Diagnosis and assessment of the asthmas. *J Allergy Clin Immunol Pract* 11, 1: 1–8, 2023.
98. Pérez de Llano, L., Tran, T. N., Al-Ahmad, M. et al. Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the International Severe Asthma Registry (ISAR). *Am J Respir Crit Care Med* 201: A4525, 2020.
99. Pérez de Llano, L., Dávila, I., Martínez-Moragón, E et al.; FEOS Study Group. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: The FEV₁, exacerbations, oral corticosteroids, symptoms score. *J Allergy Clin Immunol Pract* 9, 7: 2725–2731, 2021.
100. Pérez de Llano, L., Dacal Rivas, D., Marina Malanda, N. et al. The response to biologics is better in patients with severe asthma than in patients with asthma-COPD overlap syndrome. *J Asthma Allergy* 15: 363–369, 2022.
101. Peters, M. C., Kerr, S., Dunican, E. M. et al.; National Heart, Lung and Blood Institute Severe Asthma Research Program 3. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. *J Allergy Clin Immunol* 143, 1: 104–113, 2019.
102. Politis, J., Bardin, P. G. Switching biological therapies in adults with severe asthma: What are the dilemmas and is it worthwhile? *Ann Am Thorac Soc* 19, 12: 1965–1970, 2022.
103. Olivieri, M., Heinrich, J., Schlünssen, V. et al. The risk of respiratory symptoms on allergen exposure increases with increasing specific IgE levels. *Allergy* 71, 6: 859–868, 2016.
104. Ramonell, R. P., Lee, F. E., Swenson, C., Kuruvilla, M. Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series. *J Allergy Clin Immunol Pract* 8, 2: 742–743, 2020.
105. Requena, G., van den Bosch, J., Akuthota, P. et al. Clinical profile and treatment in hypereosinophilic syndrome variants: A pragmatic review. *J Allergy Clin Immunol Pract* 10, 8: 2125–2134, 2022.
106. Rodriguez, A. A., Chavez, D., Benzaquen, S. Bronchial thermoplasty for the treatment of severe persistent asthma. *Curr Opin Pulm Med* 29, 1: 43–46, 2023.
107. Roufosse, F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. *Front Med (Lausanne)* 5: 49, 2018.
108. Růžicková Kirchnerová, O., Teřl, M., Mírka, H. et al. Alergická bronchopulmonální aspergilóza (ABPA) a možnosti její léčby. *Stud Pneumol Phtiseol* 70, 4: 149–154, 2010.
109. Saxena, P., Choudhary, H., Muthu, V. et al. Which are the optimal criteria for the diagnosis of allergic bronchopulmonary aspergillosis? A latent class analysis. *J Allergy Clin Immunol Pract* 9, 1: 328–335, 2021.
110. Shomali, W., Gotlib, J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. *Am J Hematol* 99, 5: 946–968, 2024.
111. Schatz, M., Rosenwasser, L. The allergic asthma phenotype. *J Allergy Clin Immunol Pract* 2, 6: 645–648, 2014.
112. Schreiber, J., Bröker, B. M., Ehmann, R., Bachert, C. Nonatopic severe asthma might still be atopic: Sensitization toward *Staphylococcus aureus* enterotoxins. *J Allergy Clin Immunol* 143, 6: 2279–2280, 2019.
113. Simpson, J. L., Yang, I. A., Upham, J. W. et al. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. *BMC Pulm Med* 16, 1: 67, 2016.
114. Sin, D. D., Miravittles, M., Mannino, D. M. et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. *Eur Respir J* 48, 3: 664–673, 2016.
115. Svenningsen, S., Nair, P. Asthma endotypes and an overview of targeted therapy for asthma. *Front Med (Lausanne)* 4: 158, 2017.
116. Sze, E., Bhalla, A., Nair, P. Mechanisms and therapeutic strategies for non-T₂ asthma. *Allergy* 75, 2: 311–325, 2020.
117. Szeffler, S. J., Wenzel, S., Brown, R. et al. Asthma outcomes: biomarkers. *J Allergy Clin Immunol* 129, Suppl. 3: S9–S23, 2012.

118. Teřl, M., Sedlák, V., Čáp, P. et al. Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. *Allergy* 72, 9: 1279–1287, 2017.
119. Teřl, M., Pohunek, P., Kuhn, M., Bystroň, J. Four seasons of Czech asthma study: asthma characteristics and management reality in the Czech Republic. *J Asthma* 57, 8: 898–910, 2020.
120. Teřl, M., Jesenák, M. Managing T2-high severe asthma in HIV-infected patients. *J Allergy Clin Immunol Pract* 9, 2: 1041–1043, 2021.
121. Teřl, M. et al. Doporučený postup diagnostiky a léčby astmatu. Semily: GEUM, 2015. (online: www.pneumologie.cz/guidelines) [cit. 12. 3. 2023]
122. Tiotiu, A. Applying personalized medicine to adult severe asthma. *Allergy Asthma Proc* 42, 1: e8–e16, 2021.
123. Thomas, D., McDonald, V. M., Pavord, I. D., Gibson, P. G. Asthma remission: what is it and how can it be achieved? *Eur Respir J* 60, 5: 2102583, 2022.
124. Tonga, K. O., Chapman, D. G., Farah, C. S. et al. Reduced lung elastic recoil and fixed airflow obstruction in asthma. *Respirology* 25, 6: 613–619, 2020.
125. Upham, J. W., Le Lievre, Ch., Jackson, D. J. et al. Defining a severe asthma super-responder: findings from a delphi process. *J Allergy Clin Immunol Pract* 9, 11: 3997–4004, 2021.
126. Vaník, P., Novosad, J., Kirchnerová, O. et al.; Czech Anti-IgE Registry collaborators. Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry. *Allergy Asthma Clin Immunol* 16: 81, 2020.
127. van der Veer, T., Dallinga, M. A., van der Valk, J. P. M. et al. Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab. *Clin Transl Allergy* 11, 10: e12081, 2021.
128. Walsh, G. M. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update. *Expert Rev Clin Immunol* 13, 2: 143–149, 2017.
129. Wechsler, M. E., Akuthota, P., Jayne, D. et al.; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med* 376, 20: 1921–1932, 2017.
130. Wenzel, S. E., Castro, M., Corren, J. et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 388, 10039: 31–44, 2016.
131. Wenzel, S. E. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. *Am J Respir Crit Care Med* 203, 7: 809–821, 2021.
132. White, J., Dubey, S. Eosinophilic granulomatosis with polyangiitis: A review. *Autoimmun Rev* 22, 1: 103219, 2023.
133. Wu, J. Z., Ma, L. J., Zhao, L. M. et al. Significance of fractional exhaled nitric oxide combined with serum procalcitonin and C-reactive protein in evaluation of elderly asthma. *J Huazhong Univ Sci Technol Med Sci* 33, 2: 185–188, 2013.
134. Yamasaki, A., Okazaki, R., Harada, T. Neutrophils and asthma. *Diagnostics (Basel)* 12, 5: 1175, 2022.
135. GINA Difficult-to-treat and severe asthma in adolescent and adult patients. Update 2021. (online: <http://ginasthma.org>)
136. Sorkness, R. L., Bleecker, E. R., Busse, W. W. et al.; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. *J Appl Physiol* (1985) 104, 2: 394–403, 2008.
137. Kraft, M., Richardson, M., Hallmark, B. et al.; ATLANTIS study group. The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. *Lancet Respir Med* 10, 7: 661–6618, 2022.
138. Baraldi, F., Alfano, F., Contoli, M., Papi, A. Small Airway Disease in Asthma: Why is it so important? *Arch Bronconeumol* 58, 6: 471–473, 2022.
139. Diamant, Z., Vijverberg, S., Alving, K. et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper. *Allergy* 74, 10: 1835–1851, 2019.
140. Jesenak, M., Diamant, Z. Blood eosinophils: In quest of a Holy Grail for personalized asthma treatment with biologicals. *Allergy* 75, 6: 1294–1297, 2020.
141. Lugogo, N. L., Kreindler, J. L., Martin, U. J. et al. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. *Ann Allergy Asthma Immunol* 125, 2: 171–176, 2020.
142. SPC/úhradová kritéria SÚKL léčivých přípravků s obsahem jednotlivých účinných látek (biologik). (online: <https://www.sukl.cz/modules/medication/search.php>)
143. SPC léčivých přípravků s obsahem dupilumabu. (online: <https://www.sukl.cz/modules/medication/>)
144. Fukakusa, M., Bergeron, C., Tulic, M. K. et al. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. *J Allergy Clin Immunol* 115, 2: 280–286, 2005.
145. Holgate, S. T., Wenzel, S., Postma, D. S. et al. Asthma. *Nat Rev Dis Primers* 1, 1: 15025, 2015.
146. Jesenak, M., Zelieskova, M., Babusikova, E. Oxidative stress and bronchial asthma in children – causes or consequences? *Front Pediatr* 5: 162, 2017.
147. Kozik, A., Huang, Y. J. Ecological interactions in asthma: from environment to microbiota and immune responses. *Curr Opin Pulm Med* 26, 1: 27–32, 2020.
148. González-Díaz, S. N., Villarreal-Gonzalez, R. V., De Lira-Quezada, C. E., Guzman-Avilan, R. I. Outcome measures to be considered on asthma in elderly. *Curr Opin Allergy Clin Immunol* 19, 3: 209–215, 2019.
149. McDonald, V. M., Gibson, P. G. Treatable traits in asthma: moving beyond diagnostic labels. *Med J Aust* 216, 7: 331–333, 2022.
150. Diamant, Z., van den Berge, M., Hanania, N. A. Editorial: Asthma: a modifiable disease on a crossroad. *Curr Opin Pulm Med* 26, 1: 1–2, 2020.
151. Cowan, D. C., Cowan, J. O., Palmay, R. et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. *Thorax* 65, 5: 384–390, 2010.
152. Kršek, M. Systémová léčba glukokortikoidy: praktický pohled. *Vnitř Lék* 61, 10: 905–912, 2015.
153. Hamada, K., Oishi, K., Murata, Y. et al. Feasibility of discontinuing biologics in severe asthma: An algorithmic approach. *J Asthma Allergy* 14: 1463–1471, 2021.
154. Assaf, S. M., Hanania, N. A. Biological treatments for severe asthma. *Curr Opin Allergy Clin Immunol* 19, 4: 379–386, 2019.
155. Fox, H. M., Rotolo, S. M. Combination anti-IgE and anti-IL5 therapy in a pediatric patient with severe persistent asthma. *J Pediatr Pharmacol Ther* 26, 3: 306–310, 2021.
156. Dixon, A. E., Poynter, M. E. Mechanism of asthma in obesity. Pleiotropic aspects of obesity produce distinct asthma phenotypes. *Am J Respir Cell Mol Biol* 54, 5: 601–608, 2016.
157. Denning, D. W., O'Driscoll, B. R., Hogaboam, C. M. et al. The link between fungi and severe asthma: a summary of the evidence. *Eur Respir J* 27, 3: 615–626, 2006.
158. Wenzel, S. Severe asthma: from characteristic to phenotypes to endotypes. *Clin Exp Allergy* 42, 5: 650–658, 2012.
159. Godar, M., Blanchetot, C., de Haard, H. et al. Personalized medicine with new biologics for severe type 2 asthma: current status and future prospects. *MAbs* 10, 1: 34–45, 2018.
160. Lambrecht, B. N., Hammad, H. The immunology of asthma. *Nat Immunol* 16, 1: 45–56, 2015.
161. Galli, S. J., Tsai, M., Piliponsky, A. M. The development of allergic inflammation. *Nature* 454, 7203: 445–454, 2008.
162. Smith, S. G., Chen, R., Kjarsgaard, M. et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. *J Allergy Clin Immunol* 137, 1: 75–86, 2016.
163. Bagnasco, D., Ferrando, M., Varricchi, G. et al. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. *Int Arch Allergy Immunol* 170, 2: 122–131, 2016.
164. Whittaker, L., Niu, N., Temann, U. et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. *Am J Respir Cell Mol Biol* 27, 5: 593–602, 2002.
165. Bachert, C., Humbert, M., Hanania, N. A. et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. *Eur Respir J* 55, 4: 1901592, 2020.
166. Woo, S. D., Luu, Q. Q., Park, H.-S. NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care. *Front Pharmacol* 11: 1147, 2020.

167. Nagarkar, D. R., Poposki, J. A., Comeau, M. et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. *J Allergy Clin Immunol* 130, 1: 225–232, 2012.
168. Leckie, M. J., ten Brinke, A., Kahn, J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 356, 9248: 2144–2148, 2000.
169. Gevaert, P., Omachi, T. A., Corren, J. et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol* 146, 3: 595–605, 2020.
170. Kolkhir, P., Muñoz, M., Asero, R. et al. Autoimmune chronic spontaneous urticaria. *J Allergy Clin Immunol* 149, 6: 1819–1831, 2022.
171. Dupixent 200 mg injekční roztok v předplněné injekční stříkačce. Dupixent 200 mg injekční roztok v předplněném peru. Dupixent 300 mg injekční roztok v předplněné injekční stříkačce. Dupixent 300 mg injekční roztok v předplněném peru. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/dupixent-epar-product-information_cs.pdf) [cit. leden 2026]
172. Castro, M., Corren, J., Pavord, I. D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 378, 26: 2486–2496, 2018.
173. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. *Thorax* 69, Suppl. 1: 1–192, 2014.
174. de Vries, J. E. The role of IL-13 and its receptor in allergy and inflammatory responses. *J Allergy Clin Immunol* 102, 2: 165–169, 1998.
175. Shinkai, A., Yoshisue, H., Koike, M. et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. *J Immunol* 163, 3: 1602–1610, 1999.
176. Hinks, T. S. C., Levine, S. J., Brusselle, G. G. Treatment options in type-2 low asthma. *Eur Respir J* 57, 1: 2000528, 2021.
177. Casale, T. B., Luskin, A. T., Busse, W. et al. Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. *J Allergy Clin Immunol Pract* 7, 1: 156–164, 2019.
178. Sverrild, A., Hansen, S., Hvidtfeldt, M. et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). *Eur Respir J* 59, 1: 2101296, 2021.
179. Munakata, M. Airway remodeling and airway smooth muscle in asthma. *Allergol Int* 55, 3: 235–243, 2006.
180. Sorkness, R. L., Bleecker, E. R., Busse, W. W. et al.; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. *J Appl Physiol* (1985) 104, 2: 394–403, 2008.
181. Koichiro Asano, Akira Hebisawa, Takashi Ishiguro, et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. *J Allergy Clin Immunol* 147, 4: 1261–1268, 2021.
182. Agarwal, R., Muthu, V., Sehgal, I. et al. Allergic bronchopulmonary aspergillosis. *Clin Chest Med* 43, 1: 99–125, 2022.
183. Rick, E. M., Woolnough, K., Pashley, C. H., Wardlaw, A. J. Allergic fungal airway disease. *J Investig Allergol Clin Immunol* 26, 6: 344–354, 2016.
184. Agarwal, R., Saxena, P., Muthu, V. et al. Evaluation of simpler criteria for diagnosing allergic bronchopulmonary aspergillosis complicating asthma. *Front Cell Infect Microbiol* 12: 861866, 2022.
185. Kono, Y., Tsushima, K., Yamaguchi, K. et al. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. *Respir Med* 107, 7: 1094–1100, 2013.
186. Eraso, I. C., Sangiovanni, S., Morales, E. I., Fernández-Trujillo, L. Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review. *Ther Adv Respir Dis* 14: 1753466620961648, 2020.
187. Muthu, V., Sehgal, I. S., Prasad, K. T. et al. Epidemiology and outcomes of allergic bronchopulmonary aspergillosis in the elderly. *Mycoses* 65, 1: 71–78, 2022.
188. Wardlaw, A. J., Rick, E. M., Pur Ozyigit, L. et al. New perspectives in the diagnosis and management of allergic fungal airway disease. *J Asthma Allergy* 14: 557–573, 2021.
189. Chishimba, L., Niven, R. M., Cooley, J., Denning, D. W. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. *J Asthma* 49, 4: 423–433, 2012.
190. Bini, F., Visca, D., Grassi, N. et al. Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA). *ERS Journal* 54, Suppl. 3: PA545, 2019.
191. Mümmler, C., Kemmerich, B., Behr, J. et al. Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab? *Allergy Asthma Clin Immunol* 16: 55, 2020.
192. Leung, J. M., Sin, D. D. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. *BMJ* 358: j3772, 2017.
193. Koblizek, V., Chlumsky, J., Zindr, V. et al.; Czech Pneumological and Phthysiological Society. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthysiological Society; a novel phenotypic approach to COPD with patient-oriented care. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 157, 2: 189–201, 2013. (česká verze dostupná na www.pneumologie.cz)
194. Gibson, P. G., McDonald, V. M. Asthma-COPD overlap 2015: now we are six. *Thorax* 70, 7: 683–691, 2015.
195. Barnes, P. J. Asthma-COPD overlap. *Chest* 149, 1: 7–8, 2016.
196. Menezes, A. M. B., Montes de Oca, M., Pérez-Padilla, R. et al.; PLATINO Team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. *Chest* 145, 2: 297–304, 2014.
197. Miravittles, M., Dirksen, A., Ferrarotti, I. et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1-antitrypsin deficiency. *Eur Respir J* 50, 5: 1700610, 2017.
198. Koblížek, V., Chlumský, J., Zindr, V. et al. Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN. In: Kolek, V. et al. Doporučené postupy v pneumologii. 3. aktualizované vydání. Praha: Maxdorf, 2019. (p. 18–48).
199. Chlumský, J. Standard pro diagnostiku a léčbu pacientů s CHOPN s prokázanou deficiencí alfa-1 antitrypsinu (AATD). In: Kolek, V. et al. Doporučené postupy v pneumologii. 3. aktualizované vydání. Praha: Maxdorf, 2019. (p. 48–57).
200. Hines, K. L., Peebles, R. S. Jr. Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. *Curr Allergy Asthma Rep* 17, 3: 15, 2017.
201. Albertson, T. E., Chenoweth, J. A., Pearson, S. J., Murin, S. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). *Expert Opin Pharmacother* 21, 2: 213–231, 2020.
202. Zatloukal, J., Brat, K., Neumannova, K. et al. Chronic obstructive pulmonary disease – diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthysiological Society. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 164, 4: 325–356, 2020.
203. Matsumoto, H. Bronchiectasis in severe asthma and asthmatic components in bronchiectasis. *Respir Investig* 60, 2: 187–196, 2022.
204. Crimi, C., Ferri, S., Campisi, R., Crimi, N. The link between asthma and bronchiectasis: State of the art. *Respiration* 99, 6: 463–476, 2020.
205. García-Clemente, M., Enríquez-Rodríguez, A. I., Iscar-Urrutia, M. et al. Severe asthma and bronchiectasis. *J Asthma* 57, 5: 505–509, 2020.
206. Porsbjerg, C., Menzies-Gow, A. Co-morbidities in severe asthma: Clinical impact and management. *Respirology* 22, 4: 651–661, 2017.
207. Reiter, A., Gotlib, J. Myeloid neoplasms with eosinophilia. *Blood* 129, 6: 704–714, 2017.
208. Valent, P., Klion, A. D., Horny, H. P. et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. *J Allergy Clin Immunol* 130, 3: 607–612, 2012.
209. Ackerman, S. J., Butterfield, J. H. Eosinophilia, eosinophil-associated diseases, chronic eosinophilic leukemia, and the hypereosinophilic syndromes. In: Hoffman, R., Benz, E. Jr, Shattil, S. J. et al. (eds.) *Hematology*. 4th ed. Philadelphia: Churchill Livingstone; 2005.

210. Jennette, J. C., Falk, R. J., Bacon, P. A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 65, 1: 1–11, 2013.
211. Kodet, O. Vaskulitidy z pohledu dermatologa. *Čes-slov Derm* 96, 3: 99–123, 2021.
212. Nguyen, Y., Guillevin, L. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *Semin Respir Crit Care Med* 39, 4: 471–481, 2018.
213. Chung, S. A., Langford, C. A., Maz, M. et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheumatol* 73, 8: 1366–1383, 2021.
214. Couillard, S., Connolly, C., Borg, C., Pavord, I. Asthma in pregnancy: An update. *Obstet Med* 14, 3: 135–144, 2021.
215. Chambers, C. D., Krishnan, J. A., Alba, L. et al. The safety of asthma medications during pregnancy and lactation: Clinical management and research priorities. *J Allergy Clin Immunol* 147, 6: 2009–2020, 2021.
216. Namazy, J. A., Blais, L., Andrews, E. B. et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. *J Allergy Clin Immunol* 145, 2: 528–536, 2020.
217. Shakuntulla, F., Chiarella, S. E. Safety of biologics for atopic diseases during pregnancy. *J Allergy Clin Immunol Pract* 10, 12: 3149–3155, 2022.
218. Cosío, B. G., Dacal, D., Pérez de Llano, L. Asthma-COPD overlap: identification and optimal treatment. *Ther Adv Respir Dis* 12: 1753466618805662.
219. Plaza, V., Álvarez, F., Calle, M. et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). *Arch Bronconeumol* 53, 8: 443–449, 2017.
220. Schleich, F. N., Seidel, L., Sele, J. et al. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. *Thorax* 65, 12: 1039–1044, 2010.
221. Sorino, C., Scichilone, N., D'Amato, M. et al. Asthma-COPD overlap syndrome: recent advances in diagnostic criteria and prognostic significance. *Minerva Med* 18, 3 Suppl. 1: 1–5, 2017.
222. Takiguchi, H., Asano, K. Asthma-COPD overlap syndrome (ACOS). *Nihon Rinsho* 74, 5: 778–782, 2016.
223. Tho, N. V., Park, H. Y., Nakano, Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge. *Respirology* 21, 3: 410–418, 2016.
224. Toledo-Pons, N., van Boven, J. F. M., Román-Rodríguez, M. et al. Time to move from the description of different phenotypes to the treatable traits. *PLoS One* 14, 1: e0210915, 2019.
225. Zatloukal, J., Brat, K., Neumannová, K. et al. Chronická obstrukční plicní nemoc – diagnóza a léčba stabilní nemoci, personalizovaný přístup k péči, využívající koncept léčitelných charakteristik, založený na klinických fenotypch. *Stud Pneumol Phthiseol* 83, 2: 45–80, 2023.
226. Hartinger, J., Vaněček, V., Teř, M. Klinicko-farmakologické aspekty biologické léčby. *Farmakoter Revue* 4, 6: 1–7, 2019.
227. Kelly, C., Chalmers, J. D., Crossingham, I. et al. Macrolide antibiotics for bronchiectasis. *Cochrane Database Syst Rev* 3, 3: CD012406, 2018.
228. Fuhlbrigge, A., Peden, D., Apter, A. J. et al. Asthma outcomes: exacerbations. *J Allergy Clin Immunol* 129, 3 Suppl: S34–S48, 2012.
229. Reddel, H. K., Taylor, D. R., Bateman, E. D. et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 180, 1: 59–99, 2009.
230. Jia, G., Erickson, R. W., Choy, D. F. et al.; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. *J Allergy Clin Immunol* 130, 3: 647–654.e10, 2012.
231. Chipps, B. E., Jarjour, N., Calhoun, W. J. et al. A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. *Ann Am Thorac Soc* 18, 12: 1978–1987, 2021.
232. Tezspire 210 mg injekční roztok. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/tezspire-epar-product-information_cs.pdf) [cit. leden 2026]
233. Venegas Garrido, C., Mukherjee, M., Bhalla, A., Nair, P. Airway autoimmunity, asthma exacerbations, and response to biologics. *Clin Exp Allergy* 52, 12: 1365–1378, 2022.
234. Mukherjee, M., Nair, P. Blood or sputum eosinophils to guide asthma therapy? *Lancet Respir Med* 3, 11: 824–825, 2015.
235. Krämer, I. Biosimilars [Biosimilars]. *Ther Umsch* 68, 11: 659–666, 2011.
236. Lommatzsch, M., Virchow, J. C. Asthma remission: a call for a globally standardised definition. *Lancet Respir Med* 13, 1: 2–3, 2025.
237. Ramirez-Villamizar, J., Ibarra-Enríquez, C. D., Galindo-Sánchez, J. S. et al. Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review. *World Allergy Organ J* 18, 9: 101107, 2025.
238. Fibigr, O., Teř, M. Switch biologické léčby astmatu. *Stud Pneumol Phthiseol* 85, 4: 158–163, 2025.
239. Carriera, L., Caporuscio, S., Fantò, M. et al. Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review. *Monaldi Arch Chest Dis* 95, 4, 2025.
240. Lommatzsch, M., Suhling, H., Korn, S. et al. Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations. *Allergy* 77, 9: 2839–2843, 2022.
241. Saxena, P., Choudhary, H., Muthu, V. et al. Which are the optimal criteria for the diagnosis of allergic bronchopulmonary aspergillosis? A latent class analysis. *J Allergy Clin Immunol Pract* 9, 1: 328–335, 2021.
242. Agarwal, R., Dhooria, S., Singh Sehgal, I. et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. *Chest* 153, 3: 656–664, 2018.
243. Agarwal, R., Sehgal, I. S., Muthu, V. et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. *Eur Respir J* 63, 4: 2400061, 2024. (online: <https://doi.org/10.1183/13993003.00061-2024>) [cit. 18. 1. 2026]
244. Bourdin, A., Corren, J., Shah, A. et al. Dupilumab improves lung function, asthma control and exacerbation frequency in allergic bronchopulmonary aspergillosis – Results from the phase 2 LIBERTY ABPA AIRE Study [abstract]. *Am J Respir Crit Care Med* 211, Issue Abstracts: American Thoracic Society Conference, A5230, 2025.
245. Cui, Y., Luo, L., Li, C. et al. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis* 13: 3813–3829, 2018.
246. Shim, J. S., Kim, H., Kwon, J. W. et al.; Precision Intervention in Severe Asthma (PRISM) study investigators. A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study. *World Allergy Organ J* 16, 12: 100848, 2023.
247. Muñoz, G., de Gardia, G., Buxó, M. et al. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. *Eur Respir J* 51, 1: 1701926, 2018.
248. Chalmers, J. D., Haworth, C. S., Flume, P. et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. *Eur Respir J* 66, 6: 2501126, 2025. (online: <https://doi.org/10.1183/13993003.01126-2025>) [cit. 18. 1. 2026]
249. Jackson, D. J., Wechsler, M. E., Jackson, D. J. et al.; SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. *N Engl J Med* 391, 24: 2337–2349, 2024.
250. Valent, P., Klion, A. D., Roufosse, F. et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. *Allergy* 78, 1: 47–59, 2023.
251. Nucala 100 mg injekční roztok v předplněném peru. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/nucala-epar-product-information_cs.pdf) [cit. leden 2026]
252. Šenolt, L., Bonnato, M. E., Heribanová, L. et al. Mezioborové doporučené postupy pro diagnostiku a léčbu eozinofilní granulomatózy s polyangiitidou. *Čes Revmatol* 33, 2: 57–79, 2025.
253. Naftel, J., Jackson, D. J., Coleman, M. et al. An international consensus on the use of asthma biologics in pregnancy. *Lancet Respir Med* 13, 1: 80–91, 2025.
254. Sigelko, A. D., Strek, M. E., Wolfe, K. S. Asthma in pregnancy. *Obstet Gynecol* 146, 1: 39–58, 2025.
255. Jones, C. E., Jamil, Y. Management of asthma in pregnancy. *Clin Med (Lond)* 25, 1: 100277, 2025.

256. Egan, M., Bunyavanich, S. Allergic rhinitis: the "Ghost Diagnosis" in patients with asthma. *Asthma Res Pract* 1: 8, 2015.
257. Teřl, M. Astma adolescentů. *Postgrad Med* 16, 2: 130–135, 2014.
258. Stanojevic, S., Kaminsky, D. A., Miller, M. R. et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 60, 1: 2101499, 2022.
259. Israel, E., Wechsler, M. E., Jackson, D. J., Moore, W. C. Anti-cytokine biologics for asthma in adults. *Lancet* 406, 10516: 2282–2294, 2025.
260. Lindsley, A. W., Lugogo, N., Reeh, K. A. G. et al. Asthma biologics across the T2 spectrum of inflammation in severe asthma: Biomarkers and mechanism of action. *J Asthma Allergy* 18: 33–57, 2025.
261. Nolasco, S., Crimi, C. Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. *Med* 5, 12: 1452–1455, 2024.
262. Tashiro, H., Kurihara, Y., Kuwahara, Y., Takahashi, K. Impact of obesity in asthma: Possible future therapies. *Allergol Int* 73, 1: 48–57, 2024.
263. Peters, U., Dixon, A. Ee., Forno, E. Obesity and asthma. *J Allergy Clin Immunol* 141, 4: 1169–1179, 2018.
264. Kaplan, A., Heatley, H., Townend, J. et al. The real-world impact of glucagon-like peptide 1 receptor agonists on asthma control in people with high-risk asthma and obesity. *Adv Ther* 42, 6: 2950–2956, 2025.
265. Novosad, J., Krčmová, I. Biologická léčba eosinofilních fenotypů těžkého bronchiálního astmatu. *Stud Pneumol Phthiseol* 78, 4: 122–133, 2018.
266. Novosad, J., Krčmová, I. Komplexní role IL-5 v patogenezi eozinofilního astmatu. *Stud Pneumol Phthiseol* 88, 4: 109–121, 2024.
267. Novosad, J., Krčmová, I., Souček, O. et al. Subsets of eosinophils in asthma, a challenge for precise treatment. *Int J Mol Sci* 24, 6: 5716, 2023.
268. Teřl, M., Voláková, E., Fibigr, O. et al. Astma a respirační specialisté v České republice – zpráva o situaci u adolescentů a dospělých. *Stud Pneumol Phthiseol* 85, 4: 126–134, 2025.
269. Fasentra 30 mg injekční roztok v předplněné injekční stříkačce. Fasentra 30 mg injekční roztok v předplněném injekčním peru. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/fasentra-epar-product-information_cs.pdf) [cit. leden 2026]
270. Xolair 75 mg injekční roztok v předplněné injekční stříkačce. Xolair 150 mg injekční roztok v předplněné injekční stříkačce. Xolair 300 mg injekční roztok v předplněném injekčním peru. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/xolair-epar-product-information_cs.pdf) [cit. leden 2026]
271. Omlyclo 75 mg injekční roztok v předplněném peru. Omlyclo 150 mg injekční roztok v předplněném peru/v předplněné injekční stříkačce. Souhrn údajů o přípravku. (online: https://www.ema.europa.eu/cs/documents/product-information/omlyclo-epar-product-information_cs.pdf) [cit. leden 2026]
272. Stanojevic, S., Kaminsky, D. A., Miller, M. R. et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 60, 1: 2101499, 2022.
273. Teřl, M. Co je a co už není alergické astma. *Alergie* 27, 3: 153–160, 2025.
274. Terl, M., Diamant, Z., Kosturiak, R., Jesenak, M. Choosing the right biologic treatment for individual patients with severe asthma – Lessons learnt from Picasso. *Respir Med* 234: 107766, 2024.
275. Pellegrino, R., Viegi, G., Brusasco, V. et al. Interpretative strategies for lung function tests. *Eur Respir J* 26, 5: 948–968, 2005.
276. Novosad, J., Krčmová, I. Komplexní role IL-5 v patogenezi eozinofilního astmatu. *Stud Pneumol Phthiseol* 84, 4: 109–121, 2024.